{"id":7033,"date":"2023-12-20T08:00:00","date_gmt":"2023-12-20T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/"},"modified":"2023-12-20T08:00:00","modified_gmt":"2023-12-20T07:00:00","slug":"nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/","title":{"rendered":"Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA"},"content":{"rendered":"
\n

Nanexa AB meddelar idag att den kliniska pr\u00f6vningsans\u00f6kan f\u00f6r fas I-studien av NEX-22 i patienter med typ 2-diabetes har emottagits och validerats av den europeiska l\u00e4kemedelsmyndigheten EMA.<\/strong><\/p>\n<\/div>\n

\n

\u201dEMA har nu gjort sin validering av ans\u00f6kan som ett f\u00f6rsta steg och Nanexa \u00e4r vidare i den process d\u00e4r vi f\u00f6rv\u00e4ntas besvara fr\u00e5gor p\u00e5 den dokumentation och de data som ligger till grund f\u00f6r ans\u00f6kan. V\u00e5rt m\u00e5l \u00e4r att kunna starta fas I-studien baserat p\u00e5 ett godk\u00e4nnande under f\u00f6rsta kvartalet 2024, vilket vi verkligen ser fram emot\u201d, s\u00e4ger David Westberg, vd f\u00f6r Nanexa. <\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar idag att den kliniska pr\u00f6vningsans\u00f6kan f\u00f6r fas I-studien av NEX-22 i patienter med typ 2-diabetes har emottagits och validerats av den europeiska l\u00e4kemedelsmyndigheten EMA.<\/p>\n","protected":false},"template":"","class_list":["post-7033","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att den kliniska pr\u00f6vningsans\u00f6kan f\u00f6r fas I-studien av NEX-22 i patienter med typ 2-diabetes har emottagits och validerats av den europeiska l\u00e4kemedelsmyndigheten EMA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\\\/\",\"name\":\"Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2023-12-20T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA - Nanexa AB","og_description":"Nanexa AB meddelar idag att den kliniska pr\u00f6vningsans\u00f6kan f\u00f6r fas I-studien av NEX-22 i patienter med typ 2-diabetes har emottagits och validerats av den europeiska l\u00e4kemedelsmyndigheten EMA.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/","name":"Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2023-12-20T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-kliniska-provningsansokan-for-nex-22-fas-i-studie-emottagen-av-ema\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexas kliniska pr\u00f6vningsans\u00f6kan f\u00f6r NEX-22 fas I-studie emottagen av EMA"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}